MREO

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +0.15
Percentage change 7.04	%

Peers: SRPT FATE KURA ADVM RIGL XERS IMUX PRQR CLSD MTEM

| Held by: HRTS CANC IDNA GWX BBC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.29	Insider Own	9.96%	Shs Outstand	155.15M	Perf Week	24.59%
Market Cap	353.74M	Forward P/E	-	EPS next Y	-0.03	Insider Trans	0.00%	Shs Float	139.69M	Perf Month	-11.63%
Income	-43.35M	PEG	-	EPS next Q	-0.01	Inst Own	66.28%	Short Float	4.69%	Perf Quarter	-21.38%
Sales	0.00M	P/S	-	EPS this Y	26.19%	Inst Trans	21.55%	Short Ratio	4.88	Perf Half Y	-49.78%
Book/sh	0.39	P/B	5.80	EPS next Y	36.02%	ROA	-	Short Interest	6.54M	Perf Year	-15.24%
Cash/sh	0.45	P/C	5.07	EPS next 5Y	17.79%	ROE	-	52W Range	1.58 - 5.02	Perf YTD	-34.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	34.82%	ROI	-70.88%	52W High	-54.58%	Beta	0.52
Dividend TTM	-	Quick Ratio	5.40	Sales past 5Y	-40.00%	Gross Margin	-	52W Low	44.76%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	5.40	EPS Y/Y TTM	-17.36%	Oper. Margin	-	RSI (14)	52.34	Volatility	9.48% 9.57%
Employees	36	Debt/Eq	0.11	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.11	Target Price	7.30
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	1.14	Prev Close	2.13
Sales Surprise	-100.00%	EPS Surprise	22.48%	Sales Q/Q	-	Earnings	Mar 26 BMO	Avg Volume	1.34M	Price	2.28
SMA20	6.37%	SMA50	-7.27%	SMA200	-35.65%	Trades		Volume	1,258,643	Change	7.04%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-25	Initiated	JP Morgan	Overweight	$7
Dec-06-24	Initiated	Jefferies	Buy	$7
Jun-13-24	Initiated	Robert W. Baird	Outperform	$8
Oct-13-23	Resumed	BTIG Research	Buy	$4
Aug-12-22	Initiated	Cantor Fitzgerald	Overweight	$4
May-05-21	Initiated	BTIG Research	Buy	$10
Apr-05-21	Initiated	Needham	Buy	$10

Apr-16-25 03:00PM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.50%
11:23AM	Is Mereo BioPharma Group (NASDAQ:MREO) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-26-25 07:30AM	Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Mar-20-25 12:00PM	MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-05-25 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
11:00AM	Loading…
Feb-11-25 11:00AM	Mereo Insurance forays into reinsurance market (Life Insurance International)
Feb-10-25 02:12PM	Ex-AIG Chief Secures $700 Million for Mereo Reinsurance Startup (Bloomberg)
Jan-12-25 11:05AM	Mereo BioPharma Provides Update on Lead Clinical Programs (GlobeNewswire)
Jan-07-25 07:30AM	Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:50PM	Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey) -5.63%
Dec-07-24 05:20AM	Mereo BioPharma initiated with a Buy at Jefferies (TipRanks)
Dec-06-24 01:18PM	Mereo BioPharma Stock Climbs Following Jefferies' Buy Rating, Upside Potential of 89% (GuruFocus.com) +8.65%
Nov-14-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire) -5.68%
Nov-12-24 07:30AM	Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-16-24 09:06AM	Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds? (Insider Monkey)
08:21AM	Loading…
Sep-18-24 08:21AM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.84%
Sep-12-24 05:35PM	Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference (GlobeNewswire) -5.79%
Aug-13-24 08:00AM	Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-15-24 11:42PM	Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount (Investing.com)
Jun-14-24 07:50AM	Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market (GlobeNewswire) +6.52%
Jun-12-24 07:45AM	Ultragenyx, Mereo drug reduces fractures in bone disorder study (BioPharma Dive) +8.81%
Jun-11-24 05:47PM	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-30-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.90%
May-15-24 04:01PM	Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +7.09%
Apr-12-24 09:35AM	MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-03-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 05:27PM	Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results (GuruFocus.com) +10.00%
04:01PM	Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
07:00AM	Loading…
Jan-08-24 07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks)
Oct-23-23 04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire) -7.89%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-21-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -5.67%
Sep-07-23 07:30AM	Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update (GlobeNewswire)
Aug-10-23 11:04PM	BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC (GuruFocus.com) -6.30%
Aug-04-23 08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Jul-07-23 07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks) +7.32%
Jul-06-23 08:00AM	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-31-23 07:00AM	Mereo BioPharma to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 01:43PM	Phase 2 Data from ASTRAEUS Trial of Mereo BioPharmas Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference (GlobeNewswire) -5.47%
May-08-23 12:46PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-05-23 04:06PM	Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market (GlobeNewswire)
Apr-21-23 12:00PM	What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now? (Zacks) -5.72%
Apr-13-23 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-28-23 04:30PM	Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
Mar-21-23 06:30AM	Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease (GlobeNewswire) +16.89%
Feb-08-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-10-23 05:35AM	Positive week for Mereo BioPharma Group plc (NASDAQ:MREO) hedge funds investors who lost 33% over the past year (Simply Wall St.) -7.12%
Nov-15-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +5.92%
Nov-08-22 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-22 04:01PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire) -6.97% -8.76%
Oct-28-22 07:00AM	Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management (GlobeNewswire)
Oct-24-22 04:30PM	Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022 (GlobeNewswire)
Oct-21-22 07:00AM	Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting (GlobeNewswire)
Oct-18-22 11:58AM	Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan (Business Wire)
07:00AM	Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value (GlobeNewswire)
Oct-17-22 07:00AM	Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease (GlobeNewswire)
Oct-03-22 05:00PM	Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders (GlobeNewswire) +7.85%
09:00AM	Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five (Business Wire)
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks (Insider Monkey)
Sep-26-22 07:00AM	Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board (GlobeNewswire)
Sep-14-22 09:00AM	Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders (Business Wire)
Sep-12-22 08:00AM	Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors (GlobeNewswire)
Sep-09-22 08:22PM	Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR (GlobeNewswire) +5.94%
Aug-31-22 07:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Aug-22-22 04:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Jul-05-22 04:01PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.52%
Jun-21-22 08:30AM	CEOs of NIO, NEXCF, MREO, and AIMLF Advancing Next Wave of Multi-Billion Dollar Growth Opportunities in Web 3.0, Wearables, Pharma, and Electric Vehicles. (GlobeNewswire) +30.00%
Jun-20-22 10:36AM	Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout (Zacks)
Jun-17-22 05:30PM	Mereo BioPharm and Theseus Pharmaceuticals See Action From Activist Investors (Barrons.com) +62.50% +30.00%
03:53PM	AstraZeneca weighs bid for Mereo, Carnival Cruises partners with MGM, Devon Energy stock plunges (Yahoo Finance Video)
10:21AM	Why Mereo BioPharma Shares Are Jumping Today (Benzinga)
03:44AM	AstraZeneca weighing bid for Mereo BioPharma: report (MarketWatch)
Jun-02-22 08:00AM	Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan (GlobeNewswire) -5.12%
May-26-22 05:05PM	Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +8.77%
04:30PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire)
May-17-22 08:00AM	Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors (GlobeNewswire)
May-09-22 07:45AM	Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease (Benzinga) -31.30%
07:00AM	Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from ASTRAEUS Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema (GlobeNewswire)
May-06-22 05:12PM	Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat (GlobeNewswire)
05:12PM	Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat (GlobeNewswire)
Apr-22-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-06-22 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-22 04:01PM	Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights (GlobeNewswire) +7.69%
Mar-03-22 08:30AM	Mereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022 (GlobeNewswire)
Mar-01-22 08:00AM	Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors (GlobeNewswire)
Feb-10-22 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -6.67%
Jan-12-22 01:59PM	Do Hedge Funds Love Mereo BioPharma Group plc (MREO)? (Insider Monkey)
Dec-29-21 01:19AM	UAB and Mereo BioPharma Group post positive results from Covid-19 clinical trial (American City Business Journals)
Dec-22-21 07:00AM	UAB and Mereo Announce Positive Top-line Results from COSTA a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease (GlobeNewswire)
Dec-17-21 12:38AM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com) +7.55%
Dec-15-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com)
Dec-13-21 07:00AM	Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereos Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting (GlobeNewswire)
Dec-10-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com)
Nov-30-21 07:00AM	Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors (GlobeNewswire)
Nov-09-21 08:00AM	Mereo BioPharma to Present at Two Upcoming Investor Conferences (GlobeNewswire)

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scots-Knight Denise	Chief Executive Officer	Sep 13 '24	Sale	4.22	60,046	253,454	808,921	Sep 16 08:50 PM
Scots-Knight Denise	Chief Executive Officer	Sep 12 '24	Sale	4.47	28,611	127,968	868,967	Sep 16 08:50 PM
Lewicki John A.	Chief Scientific Officer	Sep 13 '24	Sale	4.22	10,937	46,165	78,630	Sep 16 08:49 PM
Lewicki John A.	Chief Scientific Officer	Sep 12 '24	Sale	4.47	5,212	23,312	89,567	Sep 16 08:49 PM
Sermon Charles	General Counsel	Sep 13 '24	Sale	4.22	20,946	88,413	219,061	Sep 16 08:48 PM
Sermon Charles	General Counsel	Sep 12 '24	Sale	4.47	9,980	44,638	240,007	Sep 16 08:48 PM
Fox Christine Ann	Chief Financial Officer	Sep 13 '24	Sale	4.22	19,158	80,866	89,285	Sep 16 08:47 PM
Fox Christine Ann	Chief Financial Officer	Sep 12 '24	Sale	4.47	9,128	40,827	108,443	Sep 16 08:47 PM
Hughes-Wilson Alexandra	See Remarks	Sep 13 '24	Sale	4.22	100,312	423,417	50,475	Sep 16 08:46 PM
Hughes-Wilson Alexandra	See Remarks	Sep 12 '24	Sale	4.47	47,798	213,786	150,787	Sep 16 08:46 PM
Sermon Charles	General Counsel	Sep 11 '24	Option Exercise	0.00	65,600	0	249,987	Sep 13 04:57 PM
Fox Christine Ann	Chief Financial Officer	Sep 11 '24	Option Exercise	0.00	60,000	0	117,571	Sep 13 04:50 PM
Lewicki John A.	Chief Scientific Officer	Sep 11 '24	Option Exercise	0.00	46,000	0	94,779	Sep 13 04:49 PM
Scots-Knight Denise	Chief Executive Officer	Sep 11 '24	Option Exercise	0.00	188,060	0	897,578	Sep 13 04:49 PM
Hughes-Wilson Alexandra	See Remarks	Sep 11 '24	Option Exercise	0.99	208,333	206,416	242,881	Sep 13 04:47 PM
Alexandra Hughes-Wilson	Officer	Sep 12 '24	Proposed Sale	4.66	148,110	690,193		Sep 12 04:05 PM
Scots-Knight Denise	Officer	Sep 12 '24	Proposed Sale	4.66	88,657	413,142		Sep 12 04:05 PM
Sermon Charles	Officer	Sep 12 '24	Proposed Sale	4.66	30,926	144,115		Sep 12 04:05 PM
Lewicki John A.	Officer	Sep 12 '24	Proposed Sale	4.66	16,149	75,254		Sep 12 04:05 PM
Fox Christine Ann	Officer	Sep 12 '24	Proposed Sale	4.66	28,286	131,813		Sep 12 04:05 PM
PAKIANATHAN DEEPIKA	Director	Aug 22 '24	Option Exercise	1.44	105,244	151,116	105,244	Aug 23 06:13 PM
PAKIANATHAN DEEPIKA	Director	Aug 22 '24	Sale	4.43	105,244	466,210	0	Aug 23 06:13 PM
Deepika Pakianathan	Director	Aug 22 '24	Proposed Sale	4.43	105,244	466,210		Aug 22 06:35 PM
Sermon Charles	General Counsel	Jun 26 '24	Sale	3.39	32,187	109,217	184,387	Jun 27 04:15 PM
Sermon Charles	General Counsel	Jun 25 '24	Sale	3.69	14,202	52,461	216,574	Jun 27 04:15 PM
Lewicki John A.	Chief Scientific Officer	Jun 26 '24	Sale	3.39	16,808	57,033	48,779	Jun 27 04:15 PM
Lewicki John A.	Chief Scientific Officer	Jun 25 '24	Sale	3.69	7,416	27,394	65,587	Jun 27 04:15 PM
Fox Christine Ann	Chief Financial Officer	Jun 26 '24	Sale	3.39	29,439	99,892	57,571	Jun 27 04:15 PM
Fox Christine Ann	Chief Financial Officer	Jun 25 '24	Sale	3.69	12,990	47,984	87,010	Jun 27 04:15 PM
Scots-Knight Denise	Chief Executive Officer	Jun 26 '24	Sale	3.39	92,273	313,101	709,518	Jun 27 04:15 PM
Scots-Knight Denise	Chief Executive Officer	Jun 25 '24	Sale	3.69	40,712	150,386	801,791	Jun 27 04:15 PM
Hughes-Wilson Alexandra	See Remarks	Jun 26 '24	Sale	3.39	22,968	77,935	34,548	Jun 27 04:15 PM
Hughes-Wilson Alexandra	See Remarks	Jun 25 '24	Sale	3.69	10,134	37,434	57,516	Jun 27 04:15 PM
Lewicki John A.	Chief Scientific Officer	Jun 21 '24	Option Exercise	0.00	69,000	0	73,003	Jun 25 06:21 PM
Scots-Knight Denise	Chief Executive Officer	Jun 21 '24	Option Exercise	0.00	282,090	0	842,503	Jun 25 06:15 PM
Sermon Charles	General Counsel	Jun 21 '24	Option Exercise	0.00	98,400	0	230,776	Jun 25 06:14 PM
Fox Christine Ann	Chief Financial Officer	Jun 21 '24	Option Exercise	0.00	90,000	0	100,000	Jun 25 06:13 PM
Hughes-Wilson Alexandra	See Remarks	Jun 21 '24	Option Exercise	0.00	60,000	0	67,650	Jun 25 06:13 PM
Hughes-Wilson Alexandra	See Remarks	May 22 '24	Option Exercise	1.23	168,333	206,416	100,983	May 23 09:54 PM
Hughes-Wilson Alexandra	See Remarks	May 22 '24	Sale	2.97	100,432	297,788	32,568	May 23 09:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Mereo Biopharma Group Plc ADR

Upgrade your FINVIZ experience